Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Illumina Inc - San Diego, California-based biotechnology - Launches a new research test, co-developed with New Jersey, US-based pharmaceutical company Merck & Co Inc, to enable genomic profiling and enhance precision medicine in oncology. The test is called the Research Use Only TruSight Oncology 500 HRD test. It will allow researchers to unlock insights about the tumour genome, Illumina explains, by identifying genetic mutations used in the evaluation of homologous recombination deficiency. Homologous recombination deficiency is when the body is unable to repair double strand breaks in DNA.
The test will be available globally, excluding the US and Japan.
‘HRD status has emerged as an important biomarker in tumours that Harbor high levels of DNA damage, such as ovarian, breast, prostate, and pancreatic cancers,’ said Phil Febbo, chief medical officer at Illumina.
‘With one sample and one test, TruSight Oncology 500 HRD assay provides labs with comprehensive, accurate, sensitive results that can greatly enhance our understanding of the genomic nature of a tumour,’ he continued.
Current Illumina stock price: $183.24
12-month change: down 61%
Current Merck stock price: $88.03
12-month change: up 16%
Copyright 2022 Alliance News Limited. All Rights Reserved.